Sign In
Buy LLY
$1,131.42
+6.15 (+0.547%)
At Close: Jun 05, 2026
Eli Lilly: Tirzepatide's Winning Streak Continues
03:12pm, Tuesday, 20'th Aug 2024
Eli Lilly's key growth product tirzepatide (Mounjaro/Zepbound) continues to deliver on both fronts. Increased supply visibility led to a $3 billion increase in the full-year total revenue guidance ran
Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
12:27pm, Tuesday, 20'th Aug 2024
CNBC's Angelica Peebles reports on the latest news from Eli Lilly.
Why Eli Lilly Stock Jumped to a Record High on Tuesday
12:00pm, Tuesday, 20'th Aug 2024
Eli Lilly (LLY) stock jumped to a record high on Tuesday after clinical trial results showed tirzepatide—the active ingredient in Lilly's injectable weight-loss drug Zepbound and diabetes treatment
Eli Lilly's weight-loss drug may prevent diabetes — but there's 1 unanswered question
11:17am, Tuesday, 20'th Aug 2024
A 3-year-study of Zepbound and Mounjaro found the GLP-1 drugs can help prevent diabetes. The weekly injections cut the risk of developing diabetes by 94% among adults with high blood sugar.
Ozempic and Wegovy use among patients with depression needs more scrutiny, researchers say
11:01am, Tuesday, 20'th Aug 2024
There's a new twist in the ongoing debate over whether drugs widely used for weight loss are linked with thoughts of self-injury or suicide.
Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result
10:33am, Tuesday, 20'th Aug 2024
CNBC's Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk on the Street' to discuss results of the company's 3-year obesity study, which showed its highly popular weight loss dru
E.V. and Airline Stocks Hit Speedbumps as Eli Lilly (LLY) Drives More Growth
10:28am, Tuesday, 20'th Aug 2024
XPeng (XPEV) underperforms in earnings and Boeing (BA) faces more turbulence over concerns of its 777X test fleet. One stock continuing to shine in the markets: Eli Lilly (LLY).
Lilly's Weight-Loss Shot Zepbound Cuts Diabetes Risk, Study Says
10:16am, Tuesday, 20'th Aug 2024
Patients taking Eli Lilly & Co.'s blockbuster weight-loss shot were 94% less likely to develop diabetes in a three-year study that illuminates the long-term health benefits of treating obesity. Lilly
Preliminary Late-Stage Study Boosts Eli Lilly Stock
10:06am, Tuesday, 20'th Aug 2024
Eli Lilly And Co (NYSE:LLY) announced today preliminary results from a late-stage study indicated the main ingredients Zepbound and Mounjaro of weight-loss drug tirzepatide reduced the risk of progr
Eli Lilly's weight-loss pill shows 94% reduction in diabetes risk: Is a $1 trillion valuation next?
09:56am, Tuesday, 20'th Aug 2024
Eli Lilly & Co (NYSE: LLY) has made a groundbreaking revelation that its weight-loss drug, Tirzepatide, reduces the risk of developing type 2 diabetes by an astonishing 94% in overweight adults with p
Eli Lilly's Mounjaro cuts risk of developing Type 2 diabetes, study finds
08:47am, Tuesday, 20'th Aug 2024
Eli Lilly & Co.'s stock LLY gained more than 2% premarket on Tuesday after the drugmaker said that tirzepatide, marketed as the diabetes drug Mounjaro and weight-loss treatment Zepbound, sharply cut p
Eli Lilly says weight-loss drug cut diabetes risk by 94% in trial
06:54am, Tuesday, 20'th Aug 2024
Eli Lilly said on Tuesday its weight loss drug cut the risk of developing diabetes by 94% in patients with pre-diabetes or those who were obese or overweight in a long-term study.
Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
06:45am, Tuesday, 20'th Aug 2024
Eli Lilly's weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with pre-diabetes compared to a placebo, according to initial results from a long-term
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
06:45am, Tuesday, 20'th Aug 2024
176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date Tirzepatide resulted in sustained weight loss through the treatment period, averagin
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
01:57pm, Monday, 19'th Aug 2024
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp
